Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate

Oncotarget

Volumn 7, Issue 39, 2016, Pages 63226-63241

  Brighenti, Elisa ^a   Giannone, Ferdinando Antonino ^a,b   Fornari, Francesca ^b   Onofrillo, Carmine ^a   Govoni, Marzia ^a   Montanaro, Lorenzo ^a   Treré, Davide ^a   Derenzini, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Aspirin; Cancer; Inflammation; P53; Ribosome biogenesis

Indexed keywords

ACETYLSALICYLIC ACID; INTERLEUKIN 6; MESSENGER RNA; MYC PROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P53; PROTEIN S6; RIBOSOME RNA; UVOMORULIN; DNA DIRECTED RNA POLYMERASE; NONSTEROID ANTIINFLAMMATORY AGENT; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL PROLIFERATION; COLON MUCOSA; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; MALE; MOUSE; NONHUMAN; ORGANELLE BIOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; RIBOSOME; RNA TRANSCRIPTION; UPREGULATION; ANIMAL; C57BL MOUSE; FEMALE; HEP-G2 CELL LINE; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEOPLASM; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HEP G2 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIVER; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MYC; RIBOSOMES; RNA INTERFERENCE; RNA POLYMERASE I; RNA, RIBOSOMAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84993990024     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11441     Document Type: Article

References (67)

1. Thun MJ, Henley SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002; 94:252-266.
2. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012; 9:259-267.
3. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377:31-41.
4. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379:1602-1612.
5. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13:518-527.
6. Cao Y, Nishihara R, Wu K, Wang M, Ogino S, Willett WC, Spiegelman D, Fuchs CS, Giovannucci EL, Chan AT. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol. 2016. doi: 10.1001/jamaoncol.2015.6396.
7. Coussens LM, Werb Z. Inflammation and cancer. Historical key review on inflammation and cancer. Nature. 2002; 420:860-867.
8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454:436-444.
9. Chell S, Kadi A, Williams AC, Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of cancer. Biochim Biophys Acta. 2006; 1766:104-119.
10. Wang D, DuBois RN. Prostaglandins and cancer. Gut. 2006; 55:115-122.
11. Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals. 2012; 5:1346-1371.
12. Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin and cancer prevention. Br J Cancer. 2014; 111:61-67.
13. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009; 373:1301-1309.
14. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117:1175-1183.
15. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-899.
16. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005; 41:2502-2512.
17. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15:91-102.
18. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis associated cancer. Cancer Cell. 2009; 15:103-113.
19. He G, Karin M. NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res. 2011; 21:159-168.
20. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007; 317:121-124.
21. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010; 140:197-208.
22. Brighenti E, Calabrese C, Liguori G, Giannone FA, Trerè D, Montanaro L, Derenzini M. Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer. Oncogene. 2014; 33:4396-4406.
23. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009; 16:369-377.
24. Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene. 2010; 29:4253-4260.
25. Bursac S, Brdovcak MC, Donati G, Volarevic S. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. Biochim Biophys Acta. 2014; 1842:817-830.
26. Golomb L, Volarevic S, Oren M. p53 and ribosome biogenesis stress: the essentials. FEBS Lett. 2014; 588:2571257-9.
27. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010; 138:2101-2114.
28. Pathi S, Jutooru I, Chadalapaka G, Nair V, Lee SO, Safe S. Aspirin Inhibits Colon Cancer Cell and Tumor Growth and Downregulates Specificity Protein (Sp) Transcription Factors. PLoS ONE. 2012; 7:e48208.
29. Qiao L, Hanif R, Sphicas E, ShiffSJ, Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol. 1998; 55:53-64.
30. Redlak MJ, Power JJ, Miller TA. Aspirin-induced apoptosis in human gastric cancer epithelial cells: relationship with protein kinase C signaling. Dig Dis Sci. 2007; 52:810-816.
31. Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and-11. Anticancer Res. 1999; 19:2997-3006.
32. Kim SR, Bae MK, Kim JY, Wee HJ, Yoo MA, Bae SK. Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun. 2009; 387:342-347.
33. Tian Y, Ye Y, Gao W, Chen H, Song T, Wang D, Mao X, Ren C. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int J Colorectal Dis. 2011; 26:13-22.
34. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994; 84:1415-1420.
35. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADPribose) polymerase: an early marker of chemotherapyinduced apoptosis. Cancer Res. 1993; 53:3976-3985.
36. Dargan PI, Wallace CI, Jones AL. An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med. J 2002; 19:206-209.
37. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000; 2:76-83.
38. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283:14910-14914.
39. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun. 2001; 282:671-677.
40. White RJ. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol. 2005; 6:69-78.
41. Gomez-Roman N, Felton-Edkins ZA, Kenneth NS, Goodfellow SJ, Athineos D, Zhang J, Ramsbottom BA, Innes F, Kantidakis T, Kerr ER, Brodie J, Grandori C, White RJ. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochem Soc Symp. 2006; 73:141-154.
42. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010; 4:301-309.
43. Schlosser I, Hölzel M, Mürnseer M, Burtscher H, Weidle UH, Eick D. A role for c-MYC in the regulation of ribosomal RNA processing. Nucleic Acids Res. 2003; 31:6148-6156.
44. Ravitz MJ, Chen L, Lynch M, Schmidt EV. c-MYC Repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer Res. 2007; 67:11209-11217.
45. Robledo S, Idol RA, Crimmins DL, Ladenson JH, Mason PJ, Bessler M. The role of human ribosomal proteins in the maturation of rRNA and ribosome production. RNA. 2008; 14:1918-1929.
46. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005; 25:7432-7440.
47. Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003; 116:499-511.
48. Derenzini M. The AgNORs. Micron. 2000; 31:117-120.
49. Montanaro L, Treré D, Derenzini M. Nucleolus, ribosomes, and cancer. Am J Pathol. 2008; 173:301-310.
50. Derenzini M, Trere D, Pession A, Montanaro L, Sirri V, Ochs RL. Nucleolar function and size in cancer cells. Am J Pathol 1998; 152:1291-1297.
51. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest. 2009; 119:1420-1428.
52. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9:265-273.
53. Schmidt EV, Ravitz MJ, Chen L, Lynch M. Growth controls connect: interactions between c-myc and the tuberous sclerosis complex-mTOR pathway. Cell Cycle. 2009; 8:1344-1351.
54. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005; 100:1345-1353.
55. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323:1228-1233.
56. Shanahan F. Relation between colitis and colon cancer Lancet. 2001; 357:246-247.
57. M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126:451-459.
58. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, Rao PH, Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008; 456:971-975.
59. Signer RA, Magee JA, Salic A, Morrison SJ. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature. 2014; 509:49-54.
60. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011; 106:1911-1921.
61. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 200516; 97:1679-1687.
62. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001; 131:3109S-3120S.
63. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006; 17:328-336.
64. Donati G, Bertoni S, Brighenti E, Vici M, Treré D, Volarevic S, Montanaro L, Derenzini M. The balance between rRNA and ribosomal protein synthesis up-and downregulates the tumour suppressor p53 in mammalian cells. Oncogene. 2011; 30:3274-3288.
65. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med. 2000; 51:511-523.
66. Carnero A, Hudson JD, Price CM, Beach DH. p16(INK4a) and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol. 2000; 2:148-155.
67. Treré D. AgNOR staining and quantification. Micron. 2000; 31:127-131.